Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gary Patou acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was bought at an average price of $3.00 per share, for a total transaction of $15,000.00. Following the completion of the acquisition, the director now owns 12,028 shares of the company’s stock, valued at $36,084. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) traded down 1.82% during trading on Friday, hitting $2.70. 30,264 shares of the company’s stock traded hands. Xenon Pharmaceuticals Inc. has a 52-week low of $2.70 and a 52-week high of $9.95. The company’s market cap is $48.59 million. The company’s 50 day moving average price is $3.23 and its 200 day moving average price is $5.08.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.38 million. Analysts expect that Xenon Pharmaceuticals Inc. will post ($0.96) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Xenon Pharmaceuticals Inc. (XENE) Director Buys $15,000.00 in Stock” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://stocknewstimes.com/2017/08/12/xenon-pharmaceuticals-inc-xene-director-buys-15000-00-in-stock.html.
A number of large investors have recently made changes to their positions in XENE. K2 Principal Fund L.P. raised its stake in shares of Xenon Pharmaceuticals by 40.6% in the second quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock valued at $518,000 after buying an additional 47,535 shares during the period. Endurant Capital Management LP purchased a new stake in shares of Xenon Pharmaceuticals during the first quarter valued at $1,363,000. Sabby Management LLC purchased a new stake in shares of Xenon Pharmaceuticals during the first quarter valued at $1,186,000. KCG Holdings Inc. purchased a new stake in shares of Xenon Pharmaceuticals during the first quarter valued at $122,000. Finally, Renaissance Technologies LLC raised its stake in shares of Xenon Pharmaceuticals by 90.1% in the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock valued at $868,000 after buying an additional 102,890 shares during the period. 56.01% of the stock is owned by institutional investors.
Several research firms have commented on XENE. Jefferies Group LLC set a $5.00 price objective on shares of Xenon Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 4th. Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, July 1st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $5.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, June 27th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Xenon Pharmaceuticals has a consensus rating of “Buy” and an average price target of $11.88.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.